Multiple commercial cirDNA-based oncology assays have been approved for early detection (for example, Epi proColon® for colorectal cancer) [11], disease monitoring (for example, COLVERATM for monitoring the recurrence of colorectal cancer) [12], and precision medicine (for example, Cobas® EGFR Mutation Test v2, for the prediction of non-small cell lung cancer responses to epidermal growth factor receptor (EGFR) inhibitors) [13,14]. This evidence concerns the gene EGFR and colorectal cancer.